Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives

Hegde, Mangala; Naliyadhara, Nikunj; Unnikrishnan, Jyothsna; Alqahtani, Mohammed S.; Abbas, Mohamed; Girisa, Sosmitha; Sethi, Gautam; Kunnumakkara, Ajaikumar B.

doi:10.1016/j.canlet.2023.216066

Cited by 29 publications

(17 citation statements)

References 336 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Purified molecules or natural products can be used as adjuvants for cancer therapy. Nanotechnology has advanced applications in cancer diagnosis and therapy [162,163]. Nanoparticles can be modified with specific targeting molecules and loaded with specific chemicals to improve their therapeutic efficacy [164,165].…”

Section: Discussionmentioning

confidence: 99%

Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology

Lee,

Wu,

Cheng

et al. 2024

IJMS

View full text Add to dashboard Cite

Tissue inhibitor of metalloproteinases-3 (TIMP3) is vital in regulating several biological processes. TIMP3 exerts antitumour effects via matrix metalloproteinase (MMP)-dependent and MMP-independent pathways. Due to promoter methylation and miRNA binding, TIMP3 expression has been observed to decrease in various cancers. Consequently, the migration and invasion of cancer cells increases. Conflicting results have reported that expression levels of TIMP3 in primary and advanced cancers are higher than those in healthy tissues. Therefore, the role of TIMP3 in cancer biology and progression needs to be elucidated. This review provides an overview of TIMP3, from its biological function to its effects on various cancers. Moreover, gynaecological cancers are discussed in detail. TIMP3 has been associated with cervical adenocarcinoma as well as cancer development in serous ovarian cancer and breast cancer metastasis. However, the relationship between TIMP3 and endometrial cancers remains unclear. TIMP3 may be a useful biomarker for gynaecological cancers and is a potential target for future cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology

Lee,

Wu,

Cheng

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…In recent years, surface-engineered NPs have attracted fast-growing interest due to their ability to potentially overcome some of the most important limitations in current antitumor therapies, such as non-specific biodistribution, inefficient accumulation in tumor tissues and the apparition of multidrug resistance (MDR) [ 18 , 41 , 85 ]. Regarding the specific matter of CRC, more than one hundred studies have been published concerning the preclinical evaluation of nanomedicines [ 18 ].…”

Section: Antibody-loaded Nanosystems For the Therapy Of Crcmentioning

confidence: 99%

Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update

et al. 2023

View full text Add to dashboard Cite

At present, colorectal cancer (CRC) is the second deadliest type of cancer, partly because a high percentage of cases are diagnosed at advanced stages when tumors have already metastasized. Thus, there is an urgent need to develop novel diagnostic systems that allow early detection as well as new therapeutic systems that are more specific than those currently available. In this context, nanotechnology plays a very important role in the development of targeted platforms. In recent decades, many types of nanomaterials with advantageous properties have been used for nano-oncology applications and have been loaded with different types of targeted agents, capable of recognizing tumor cells or biomarkers. Indeed, among the different types of targeted agents, the most widely used are monoclonal antibodies, as the administration of many of them is already approved by the main drug regulatory agencies for the treatment of several types of cancer, including CRC. In this way, this review comprehensively discusses the main drawbacks of the conventional screening technologies and treatment for CRC, and it presents recent advances in the application of antibody-loaded nanoplatforms for CRC detection, therapy or theranostics applications.

show abstract

“…Currently, the problem of hypoxia in tumor tissues is typically addressed from two perspectives. The first approach involves the use of a nanoparticle platform in combination with drugs to inhibit the expression of hypoxia-inducible factor HIF-1α or alleviate drug resistance during treatment by combining drugs with nanoparticles, as well as the use of a nanoparticle platform in combination with a catalyst to increase the oxygen content of the microenvironment [11] , or the use of nanomaterials such as perfluorocarbons (PFCs), hemoglobin (Hb), and metal-organic skeletons (MOFs) to conserve and release large amounts of oxygen to supply the treatment [12] . The relevant research indicates that nanocarrier-based therapeutic approaches have shown significant advantages in pharmacokinetics, biodistribution, and therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…Current research focuses on reducing the toxicity of existing nanocarriers and exploring advanced nanocarriers with lower toxicity as the main target [13] . Issues related to the formulation, toxicity and safety of nanoparticles still need to be addressed in further research in clinical settings [11,14] . The second approach is to increase the oxygen content inside the tumor by directly delivering oxygen.…”

Section: Introductionmentioning

confidence: 99%

Hypoxia-improving strategy based on human-derived hemoglobin-based oxygen carriers for breast cancer monitored in vivo by functional photoacoustic mesoscopy

Qin,

Lv,

Han

et al. 2023

Optics in Health Care and Biomedical Optics XIII

View full text Add to dashboard Cite

Hypoxia in malignant tumors can have an inhibitory effect on photodynamic therapy, chemotherapy, radiotherapy, immunotherapy, and chemodynamic therapy. In previous studies, nanoparticle platforms combined with drugs or direct oxygen-carrying to increase oxygen content are usually used. Here, we designed to improve tumor hypoxia by injecting human-derived hemoglobin-based oxygen carriers (h-HBOC) synthesized from expired human blood or human placental blood, and real-time quantitative oxygen concentration monitoring was achieved with the help of photoacoustic mesofunctional imaging, and the oxygen concentration was calculated using a multispectral unmixing method. Firstly, we combined photoacoustic mesoscopy to monitor the blood oxygen concentration of the same batch of mice injected with different concentrations of h-HBOC, and verified the positive correlation between the h-HBOC concentration and the blood oxygen level without affecting the hemoglobin of the animals themselves. The relative optimal dose of h-HBOC for targeting 4T1 tumor line mice was determined to be 600 mg/kg, with the sixth hour after h-HBOC injection being the relative optimal moment of treatment. A method for determining the optimal moment of tumor microenvironment by real-time monitoring of blood oxygenation in malignant tumors has been developed to determine the optimal time of treatment for therapeutic means. This therapeutic strategy can formulate differentiated and visualized therapeutic strategies for individual individuals according to different tumor lineages and bio-individuals, bridging the individual differences and obtaining the optimal therapeutic plan. Since the improvement of tumor microenvironment by h-HBOC is sustained in the long term and can be used to improve photodynamic therapy, and chemotherapy and radiotherapy have positive effects, this strategy has great potential and application for improving multimodal treatment of malignant tumors in the future.

show abstract

Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives

Cited by 29 publications

References 336 publications

Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology

Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology

Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update

Hypoxia-improving strategy based on human-derived hemoglobin-based oxygen carriers for breast cancer monitored in vivo by functional photoacoustic mesoscopy

Contact Info

Product

Resources

About